Research Article
The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting
Table 1
Patient and tumor characteristics based on recurrence score.
| | | All patients, n = 71 | RS < 11, n = 10 | RS 11–25, n = 45 | RS > 25, n = 16 | value (low/intermediate risk vs. High risk) |
| | Age | | Mean (SD), years | 56 (9) | 59 (11) | 54 (10) | 57 (6.9) | 0.52 |
| | Age category, n (%) | | ≤50 years | 23 (32) | 3 (30) | 17 (38) | 3 (19) | — | | 51–65 years | 34 (48) | 4 (40) | 19 (42) | 11 (69) | — | | 66–79 years | 14 (20) | 3 (30) | 9 (20) | 2 (12) | — |
| | Type of operation, n (%) | | WLE + SLNBx | 52 (72) | 8 (80) | 32 (71) | 12 (75) | — | | WLE + ALNDx | 9 (13) | 1 (10) | 5 (11) | 3 (19) | — | | Mx + SLNBx | 7 (10) | 0 | 6 (13) | 1 (6) | — | | Mx + ALNDx | 3 (5) | 1 (10) | 2 (5) | 0 | — |
| | Focality of tumor, n (%) | | Unifocal | 60 (85) | 8 (80) | 37 (82) | 15 (94) | 0.24 | | Multifocal | 11 (15) | 2 (20) | 8 (18) | 1 (6) | |
| | Histology, n (%) | | IDC | 62 (87) | 7 (70) | 39 (87) | 16 (100) | — | | ILC | 8 (11) | 3 (30) | 5 (11) | 0 | — | | Papillary | 1 (2) | 0 | 1 (2) | 0 | — |
| | Tumor size in the greatest dimension | | Mean (SD), mm | 19.49 (13.81) | 26.4 (31.13) | 19.96 (9.84) | 17.19 (9) | 0.11 |
| | Tumor size category, n (%) | | ≤10 mm | 11 (15) | 2 (20) | 3 (7) | 6 (38) | — | | >10–20 mm | 37 (52) | 4 (40) | 28 (62) | 5 (31) | — | | >20–30 mm | 15 (21) | 2 (20) | 10 (22) | 3 (19) | — | | >30 mm | 8 (12) | 2 (20) | 4 (9) | 2 (12) | — |
| | Tumor grade category, n (%) | | Grade 1 | 5 (7) | 1 (10) | 4 (9) | 0 (0) | — | | Grade 2 | 48 (68) | 8 (80) | 35 (78) | 5 (31) | — | | Grade 3 | 18 (25) | 1 (10) | 6 (13) | 11 (69) | — |
| | Average grade | | Mean (SD) | 2.17 (0.54) | 2 (0.47) | 2.04 (0.46) | 2.69 (0.48) | <0.001 |
| | Nodal stage, n (%) | | N0 | 37 (52) | 3 (30) | 25 (56) | 9 (56) | — | | N1 (1–3) | 32 (45) | 6 (60) | 19 (42) | 7 (44) | — | | N2 (4–9) | 1 (1.5) | 0 (0) | 1 (2) | 0 (0) | — | | N3 (>10) | 1 (1.5) | 1 (10) | 0 (0) | 0 (0) | — |
| | Size of the largest nodal disease (mm) | | Mean (SD) | 5.56 (5.36) | 2.32 (2.71) | 4.35 (5.54) | 4.28 (5.54) | 0.88 |
| | Extranodal spread, n (% of patients with positive nodes) | | Present | 11 (37) | 3 (50) | 7 (41) | 1 (17) | 0.25 |
| | ER % | | Mean (SD) | 85 (11) | 89 (8.4) | 85 (11) | 79 (12) | 0.01 |
| | PR % | | Mean (SD) | 62.2 (34.3) | 91 (5.16) | 62.3 (32.8) | 35.1 (37.6) | <0.001 |
| | Mitotic rate | | Mean (SD) | 9.25 (8.3) | 6.5 (5.76) | 6.88 (3.87) | 15.81 (12.03) | <0.001 |
| | Lymphovascular invasion, n (%) | | Present | 20 (28) | 6 (60) | 9 (20) | 5 (31) | 0.25 |
| | Ki67%, n (%) | | ≤14% | 20 (29) | 3 (33) | 15 (34) | 2 (12) | 0.1 | | >14% | 49 (71) | 6 (66) | 29 (66) | 14 (88) | |
| | Adjuvant radiotherapy, n (%) | | Received | 57 (80) | 10 (100) | 34 (76) | 13 (81) | 0.91 |
|
|
WLE, wide local excision; Mx, mastectomy; SLNBx, sentinel lymph node biopsy; ALNDx, axillary lymph node dissection; IDC, invasive ductal carcinoma, ILC, invasive lobular carcinoma.
|
